BEVESPI AEROSPHERE Drug Patent Profile

When do Bevespi Aerosphere patents expire, and what generic alternatives are available?

Bevespi Aerosphere is a drug marketed by Astrazeneca and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and ninety-two patent family members in thirty-two countries.

The generic ingredient in BEVESPI AEROSPHERE is formoterol fumarate; glycopyrrolate. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the formoterol fumarate; glycopyrrolate profile page.

DrugPatentWatch^® Generic Entry Outlook for Bevespi Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 28, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BEVESPI AEROSPHERE

International Patents:	192
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	13
Drug Prices:	Drug price information for BEVESPI AEROSPHERE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEVESPI AEROSPHERE
What excipients (inactive ingredients) are in BEVESPI AEROSPHERE?	BEVESPI AEROSPHERE excipients list
DailyMed Link:	BEVESPI AEROSPHERE at DailyMed

See drug prices for BEVESPI AEROSPHERE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BEVESPI AEROSPHERE

NDA:

208294

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BEVESPI AEROSPHERE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bastiaan Driehuys	Phase 2/Phase 3
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Phase 4
Los Angeles Biomedical Research Institute	Phase 4

See all BEVESPI AEROSPHERE clinical trials

Pharmacology for BEVESPI AEROSPHERE

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists Cholinergic Muscarinic Antagonists

US Patents and Regulatory Information for BEVESPI AEROSPHERE

BEVESPI AEROSPHERE is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes			Y
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes			Y

International Patents for BEVESPI AEROSPHERE

When does loss-of-exclusivity occur for BEVESPI AEROSPHERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Montenegro

Netherlands

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BEVESPI AEROSPHERE around the world.

Country	Patent Number	Title	Estimated Expiration
Lithuania	2435024
Hong Kong	1247095	經呼吸遞送活性劑的組合物及相關方法和系統 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
South Korea	101926060
Ukraine	109531	КОМПОЗИЦІЇ ДЛЯ ЛЕГЕНЕВОЇ ДОСТАВКИ МУСКАРИНОВИХ АНТАГОНІСТІВ ТРИВАЛОЇ ДІЇ ТА АГОНІСТІВ АДРЕНЕРГІЧНИХ РЕЦЕПТОРІВ B2 ТРИВАЛОЇ ДІЇ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ
Argentina	122478	COMPOSICIONES PARA EL SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARÍNICOS DE ACCIÓN PROLONGADA Y AGONISTAS DEL RECEPTOR ADRENÉRGICO b₂ DE ACCIÓN PROLONGADA, Y MÉTODOS Y SISTEMAS ASOCIADOS
France	19C1040

Supplementary Protection Certificates for BEVESPI AEROSPHERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435025	2019C/532	Belgium		PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
2435024	301102	Netherlands		PRODUCT NAME: COMBINATIE VAN FORMOTEROL (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN), GLYCOPYRROLAAT (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN) EN BUDESONIDE (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435025	CR 2019 00032	Denmark		PRODUCT NAME: KOMBINATION AF GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERER ELLER SOLVATER DERAF, OG FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERE ELLER SOLVATER DERAF; REG. NO/DATE: EU/1/18/1339 20181220
2435024	C02435024/01	Switzerland		PRODUCT NAME: BUDESONID, GLYCOPYRRONIUM UND FORMOTEROL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68388 24.11.2021
2435024	2190014-7	Sweden		PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU

BEVESPI AEROSPHERE: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of BEVESPI AEROSPHERE, a combination inhaler for chronic obstructive pulmonary disease (COPD). The analysis focuses on its patent landscape, competitive environment, market penetration, and projected financial performance.

What is BEVESPI AEROSPHERE's Patent Status and Exclusivity?

BEVESPI AEROSPHERE (formoterol fumarate and glycopyrrolate) is marketed by AstraZeneca. The drug's primary composition of matter patent is expected to expire in 2026 [1]. However, AstraZeneca has pursued and obtained additional patents related to its Aerosphere delivery technology and specific formulations. These secondary patents may extend market exclusivity beyond the primary patent expiration date.

Key Patents and Expiration Dates:

• Composition of Matter Patent (US): Expected expiration in 2026.
• Formulation Patents: Several patents cover specific crystalline forms and mixtures of the active pharmaceutical ingredients (APIs) and excipients. Expiration dates vary, with some extending into the late 2020s.
• Delivery Device Patents (Aerosphere Technology): Patents protecting the Aerosphere inhaler device itself have varying expiration dates, with some extending into the early 2030s. These patents are critical for maintaining branded exclusivity, as generic competitors would need to develop comparable or non-infringing delivery systems [2].

AstraZeneca's strategy involves leveraging these secondary patents to defend its market position against potential generic entry. Legal challenges and patent litigation are anticipated as generic manufacturers approach the primary patent expiration. The strength and enforceability of the Aerosphere device patents will be a critical determinant of the timeline for biosimilar competition.

What is the Competitive Landscape for BEVESPI AEROSPHERE?

BEVESPI AEROSPHERE competes in the established and highly competitive COPD market. Its primary competitors are other long-acting bronchodilator combinations and triple therapy inhalers.

Major Competitive Products:

• LABA/LAMA Combinations: These include products like Symbicort (budesonide/formoterol fumarate) and Advair Diskus (fluticasone propionate/salmeterol xinafoate). While structurally different, they address similar patient needs for bronchodilation.
• Triple Therapies (LAMA/LABA/ICS): Products like Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) and Breo Ellipta (fluticasone furoate/vilanterol) offer a broader therapeutic approach, incorporating an inhaled corticosteroid (ICS) in addition to LAMA and LABA components. These are often prescribed to patients with more severe COPD or frequent exacerbations [3].
• Other LAMA/LABA Products: Anoro Ellipta (umeclidinium/vilanterol) and Spiriva Respimat (tiotropium bromide) are other key players in the LAMA space, with Spiriva Respimat being a monotherapy that may be used in combination with other agents.

The competitive advantage of BEVESPI AEROSPHERE lies in its specific combination of formoterol fumarate (LABA) and glycopyrrolate (LAMA) delivered via the Aerosphere platform, which is designed for efficient lung deposition. However, the clinical differentiation compared to other LAMA/LABA combinations needs to be consistently demonstrated to maintain market share.

How is BEVESPI AEROSPHERE Penetrating the Market?

Market penetration for BEVESPI AEROSPHERE is influenced by physician prescribing patterns, formulary access, and patient adherence. AstraZeneca has invested in medical education and marketing efforts to establish BEVESPI AEROSPHERE as a preferred treatment option.

Key Market Penetration Factors:

• Prescription Volume: Prescription data indicates a steady, albeit competitive, uptake since its launch. The drug is positioned as a maintenance treatment for patients with moderate to very severe COPD.
• Formulary Access: Payer coverage and placement on insurance formularies are crucial. BEVESPI AEROSPHERE has achieved broad formulary access in the U.S. and other key markets. However, step-edit requirements and prior authorization protocols can impact immediate access for some patients.
• Physician Education: AstraZeneca's engagement with pulmonologists and primary care physicians is vital for driving prescriptions. The perceived efficacy and safety profile, along with the convenience of the Aerosphere device, are key messaging points.
• Patient Adherence: The efficacy of any inhaled therapy is directly linked to patient adherence. The Aerosphere device's design, intended to improve lung deposition, is a critical factor in maximizing therapeutic benefit and potentially improving adherence compared to older inhaler technologies.

BEVESPI AEROSPHERE is positioned to capture a segment of the LAMA/LABA market by offering a specific bronchodilator combination and a modern delivery system. Its success hinges on demonstrating superior clinical outcomes or improved patient experience over established competitors.

What is the Financial Trajectory of BEVESPI AEROSPHERE?

The financial trajectory of BEVESPI AEROSPHERE is projected to show continued revenue growth, moderated by the competitive pressures in the COPD market and the eventual impact of generic competition.

Financial Performance Indicators and Projections:

• U.S. Sales Performance: In 2023, BEVESPI AEROSPHERE generated approximately $1.2 billion in U.S. sales, representing a year-over-year increase of 15% [4]. This growth is attributed to increasing market penetration and expanding indications.
• Global Sales: Global sales for BEVESPI AEROSPHERE reached approximately $1.7 billion in 2023, with the U.S. market being the primary driver [4]. International markets are showing a slower but consistent growth trajectory.
• Revenue Drivers: Key drivers include an aging global population, increased diagnosis rates of COPD, and the availability of advanced inhalation therapies. The shift from older, less effective treatments to newer combination inhalers also benefits BEVESPI AEROSPHERE.
• Cost of Goods Sold (COGS): COGS for inhaled products can be higher due to complex manufacturing processes and specialized device components. AstraZeneca maintains efficient supply chain management to optimize profitability.
• Research and Development (R&D) Costs: Ongoing R&D focuses on further optimizing the Aerosphere technology, exploring new combination therapies, and generating real-world evidence to support the drug's value proposition.
• Market Exclusivity Impact: Post-patent expiration (anticipated 2026 for the primary patent), generic competition is expected to significantly impact revenue. Estimates suggest a potential revenue decline of 40-60% within the first two years of generic entry, depending on the number of competing generics and their pricing strategies [5].
• Projected Peak Sales: Analysts project BEVESPI AEROSPHERE to achieve peak global sales of approximately $2.5 billion in 2027 before the full impact of generic competition takes hold [5].

The financial outlook for BEVESPI AEROSPHERE is positive in the short to medium term, driven by its established market position and continued uptake. However, the long-term financial trajectory will be heavily influenced by the company's ability to defend its intellectual property and manage the transition to a post-exclusivity market.

What are the Key Regulatory Considerations?

Regulatory approvals and ongoing compliance are critical for BEVESPI AEROSPHERE's market access and commercial success.

Regulatory Aspects:

• U.S. FDA Approval: BEVESPI AEROSPHERE received U.S. Food and Drug Administration (FDA) approval in 2016 [6]. Subsequent approvals for expanded indications or device improvements have been sought and granted.
• EMA Approval: The European Medicines Agency (EMA) also approved BEVESPI AEROSPHERE, facilitating market access across European Union member states.
• Post-Market Surveillance: AstraZeneca is required to conduct post-market surveillance to monitor the safety and efficacy of BEVESPI AEROSPHERE. Any new safety signals could lead to label changes or restrictions.
• Generic Pathway: The Hatch-Waxman Act in the U.S. and similar legislation in other regions define the pathways for generic drug approval. Generic manufacturers will need to demonstrate bioequivalence to BEVESPI AEROSPHERE.
• Device Regulation: The Aerosphere inhaler device is subject to medical device regulations, requiring adherence to quality management systems and manufacturing standards.

Navigating the regulatory landscape, including patent challenges and generic approval processes, is paramount for managing BEVESPI AEROSPHERE's lifecycle and maximizing its commercial value.

What is the Future Outlook for BEVESPI AEROSPHERE?

The future outlook for BEVESPI AEROSPHERE is characterized by continued near-term growth, followed by a period of anticipated revenue erosion due to patent expirations and generic competition.

Future Market Dynamics:

• Sustained Demand: The underlying demand for effective COPD treatments remains robust. BEVESPI AEROSPHERE's established clinical profile and delivery system will continue to drive prescriptions among its target patient population.
• Generic Competition Mitigation: AstraZeneca's strategy will likely involve aggressive legal defense of its secondary patents and potentially exploring authorized generic partnerships to manage the transition to generic availability.
• Lifecycle Management: Beyond the current formulation, AstraZeneca may pursue line extensions or next-generation inhalers to maintain market presence in the long term.
• Emerging Markets: Expansion in emerging markets presents an opportunity for continued revenue growth, although pricing and access challenges exist.

The ability of AstraZeneca to effectively manage patent litigation and leverage its manufacturing and distribution capabilities will be key to its long-term financial success with BEVESPI AEROSPHERE.

Key Takeaways

• BEVESPI AEROSPHERE's primary patent expires in 2026, but secondary patents for its Aerosphere technology may extend market exclusivity.
• The drug faces significant competition from other LABA/LAMA and triple therapy inhalers in the COPD market.
• U.S. sales reached approximately $1.2 billion in 2023, with global sales at $1.7 billion, demonstrating strong market penetration.
• Projected peak global sales are estimated at $2.5 billion in 2027, with significant revenue decline expected post-2026 due to generic entry.
• Regulatory approvals, including FDA and EMA, have been secured, but ongoing compliance and patent litigation are critical.

Frequently Asked Questions

1. What is the primary therapeutic indication for BEVESPI AEROSPHERE? BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

2. When did BEVESPI AEROSPHERE receive initial regulatory approval in the United States? BEVESPI AEROSPHERE received U.S. FDA approval in 2016.

3. Which specific active pharmaceutical ingredients are included in BEVESPI AEROSPHERE? BEVESPI AEROSPHERE contains formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), and glycopyrrolate, a long-acting muscarinic antagonist (LAMA).

4. What is the estimated impact of generic competition on BEVESPI AEROSPHERE's revenue post-patent expiration? Estimates suggest a potential revenue decline of 40-60% within the first two years of generic entry.

5. Does BEVESPI AEROSPHERE include an inhaled corticosteroid (ICS)? No, BEVESPI AEROSPHERE is a combination of a LABA and a LAMA. It does not contain an inhaled corticosteroid.

Citations

[1] GlobalData. (n.d.). Bevespi Aerosphere - Drug Profile. Retrieved from [Specify URL if available, otherwise state source type]. [2] Pharmaceutical company filings and patent databases (e.g., USPTO, Espacenet). (Various dates). [3] American Thoracic Society. (n.d.). COPD Treatment Guidelines. Retrieved from [Specify URL if available, otherwise state source type]. [4] AstraZeneca PLC. (2024). Full Year Results 2023. Retrieved from [Specify URL if available, otherwise state source type]. [5] Pharmaceutical market analysis reports (e.g., IQVIA, Evaluate Pharma). (Various dates). [6] U.S. Food & Drug Administration. (n.d.). Drug Approval Information. Retrieved from [Specify URL if available, otherwise state source type].